Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2006;48:93-97
Published online before print June 5, 2006, doi: 10.1161/01.HYP.0000226859.42064.ea
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/1/93    most recent
01.HYP.0000226859.42064.eav1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perlini, S.
Right arrow Articles by Ferrari, A. U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perlini, S.
Right arrow Articles by Ferrari, A. U.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*DOXAZOSIN MESYLATE
*PROPRANOLOL HYDROCHLORIDE
Medline Plus Health Information
*High Blood Pressure
Related Collections
Right arrow Other myocardial biology
Right arrow Congestive
Right arrow Cardiovascular Pharmacology
Right arrow Animal models of human disease
Right arrow Hypertrophy
Right arrow Receptor pharmacology

(Hypertension. 2006;48:93.)
© 2006 American Heart Association, Inc.


Original Articles

Survival Benefits of Different Antiadrenergic Interventions in Pressure Overload Left Ventricular Hypertrophy/Failure

Stefano Perlini; Ivana Ferrero; Giuseppina Palladini; Rossana Tozzi; Chiara Gatti; Monia Vezzoli; Francesca Cesana; Maria Bianchi Janetti; Francesca Clari; Giuseppe Busca; Giuseppe Mancia; Alberto U. Ferrari

From the Clinica Medica II (S.P., I.F., G.P., R.T., F.C.), IRCCS San Matteo, Università di Pavia, Pavia, Italy; Clin Med Gen (G.B.), IRCCS Osp Maggiore, Milano, Italy; Centro Interuniversitario di Fisiologia Clinica e Ipertensione (S.P., M.V., M.B.J., G.M.), Milan, Monza and Pavia, Italy; Dipartimento di Medicina Clinica (I.F., F.C., M.B.J., G.M., A.U.F.), Prevenzione e Biotecnologie Sanitarie, Università Milano-Bicocca, Milan, Italy; and Divisione di Riabilitazione Cardiologica (A.U.F.), Ospedale San Gerardo, Monza, Italy.

Correspondence to Alberto U. Ferrari, Centro Fisiologia Clinica e Ipertensione, Via F. Sforza, 35, 20122 Milan, Italy. E-mail a.ferrari{at}hsgerardo.org

We observed previously that in rats with aortic banding (Bd), development of left ventricular (LV) hypertrophy is opposed by ß-blockade, whereas interventions interfering with {alpha}-adrenoceptor function also inhibit interstitial fibrosis. To assess whether these differential structural effects do translate into different effects on LV function and on heart failure mortality, Bd or sham Bd 8-week–old rats were randomized to vehicle treatment (Vh), chemical sympathectomy ([Sx] 6-hydroxydopamine, 150 mg/kg IP twice a week), ß-adrenoceptor blockade (propranolol [Pro], 40 mg/kg per day PO), or {alpha}-adrenoceptor blockade (doxazosin [Dox], 5 mg/kg per day PO). After monitoring survival for 10 weeks, the survivors were anesthetized to undergo echocardiography and intraarterial blood pressure measurement. Bd-Vh rats showed increased LV and lung weights, as well as LV dilation, depressed endocardial and midwall fractional shortening and a restrictive transmitral diastolic flow velocity pattern. Compared with Bd-Vh rats, all of the actively treated Bd rats showed less LV hypertrophy, LV dilation, and lung congestion but no less depression of midwall fractional shortening. In contrast, Sx and Dox but not Pro treatment were also associated with lesser degrees of diastolic dysfunction and, even more importantly, with a striking increase in survival (sham banded rats, 100%; Bd-Vh, 40%; Bd-Pro, 51%; Bd-Sx, 83%; and Bd-Dox, 82%). Although Pro, Sx, and Dox provide similar midterm protection from development of LV hypertrophy and dysfunction and from circulatory congestion, only Sx and Dox favorably affected mortality. These findings indicate that in the aortic banding rat model, {alpha}-adrenoceptors are importantly involved in the pathogenesis of cardiovascular deterioration and disease progression.


Key Words: heart failure • hypertrophy • sympathectomy • rats • receptors, adrenergic alpha • ventricular function, left




This article has been cited by other articles:


Home page
HypertensionHome page
S. Mukaddam-Daher, A. Menaouar, P.-A. Paquette, M. Jankowski, J. Gutkowska, M.-A. Gillis, Y.-F. Shi, A. Calderone, and J.-C. Tardif
Hemodynamic and Cardiac Effects of Chronic Eprosartan and Moxonidine Therapy in Stroke-Prone Spontaneously Hypertensive Rats
Hypertension, May 1, 2009; 53(5): 775 - 781.
[Abstract] [Full Text] [PDF]